ERBB2 and breast carcinoma: Furthermore, ingenuity pathway analysis of TcdB- and TcdBNXN-responsive phosphosites revealed the strong activation of the “HER-2 Signaling in Breast cancer” pathway, confirming the involvement of the EGFR-MAPK pathway in the glucosyltransferase-independent effect.